Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

[1]  D. Charney,et al.  A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. , 2021, The American journal of psychiatry.

[2]  I. Liberzon,et al.  Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial , 2020, Chronic stress.

[3]  Sophie E. Holmes,et al.  Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression , 2020, Chronic stress.

[4]  E. Fried,et al.  Network analysis of PTSD and depressive symptoms in 158,139 treatment‐seeking veterans with PTSD , 2020, Depression and anxiety.

[5]  M. Thase,et al.  Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. , 2020, The Journal of clinical psychiatry.

[6]  C. Zarate,et al.  The influence of ketamine on drug discovery in depression. , 2019, Drug discovery today.

[7]  S. Southwick,et al.  Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. , 2019, Contemporary clinical trials.

[8]  Teddy J. Akiki,et al.  The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. , 2019, Annual review of pharmacology and toxicology.

[9]  Teddy J. Akiki,et al.  Are There Effective Psychopharmacologic Treatments for PTSD? , 2018, The Journal of clinical psychiatry.

[10]  R. Lanius,et al.  Psychotic-Like Symptoms and the Temporal Lobe in Trauma-Related Disorders: Diagnosis, Treatment, and Assessment of Potential Malingering , 2018, Chronic stress.

[11]  J. Krystal,et al.  The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? , 2018, Pharmacology & therapeutics.

[12]  M. Fava,et al.  Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depres , 2019 .

[13]  Christopher R. Erbes,et al.  Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression. , 2018, The Journal of clinical psychiatry.

[14]  Dan J Stein,et al.  Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis , 2017, Psychological Medicine.

[15]  John H Krystal,et al.  Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression , 2017, Neuropsychopharmacology.

[16]  Grant D. Huang,et al.  It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group , 2017, Biological Psychiatry.

[17]  R. Shelton,et al.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.

[18]  Randon S. Welton,et al.  Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis , 2015, Journal of psychiatric practice.

[19]  Michael K Parides,et al.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. , 2014, JAMA psychiatry.

[20]  Dan V Iosifescu,et al.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.

[21]  P. Schnurr,et al.  Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. , 2013, The Journal of clinical psychiatry.

[22]  David A. Schoenfeld,et al.  The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach , 2003, Psychotherapy and Psychosomatics.

[23]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[24]  Jeffrey Deitz,et al.  Archives of General Psychiatry , 1990 .

[25]  R. Yehuda.  POST-TRAUMATIC STRESS DISORDER , 1985, The Lancet.

[26]  S. Hyman,et al.  Post-traumatic stress disorder , 2015, Nature Reviews Disease Primers.